AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23424159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (IFN β‐1a 30 μg intramuscularly weekly + glatiramer acetate 20 mg daily)
Number of subjects: 1008
Study 23424159 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 20 mg daily
Number of subjects: 1008
Study 23424159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (IFN + GA)
Number of subjects: 1008
Study 23424159 — intervention group
Group type: COMPARATOR
Intervention: Interferon β‐1a (IFN)
Number of subjects: 1008
Study 21955196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 65
Study 21955196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 32 mg
Number of subjects: 65
Study 21955196 — intervention group
Group type: COMPARATOR
Intervention: Ramelteon (all doses)
Number of subjects: 65
Study 21955196 — intervention group
Group type: COMPARATOR
Intervention: Ramelteon (up to 8 mg)
Number of subjects: 65
Study 19203773 — intervention group
Group type: EXPERIMENTAL
Intervention: Free iron/folic acid tablets (IFA)
Number of subjects: 221
Study 19203773 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal visits with prescriptions to purchase IFA
Number of subjects: 221
Study 17372318 — intervention group
Group type: COMPARATOR
Intervention: Control (0 MJ energy)
Number of subjects: 72
Study 17372318 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy (1.5 MJ)
Number of subjects: 72
Study 17372318 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy (3.0 MJ)
Number of subjects: 72
Study 17372318 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP consumption (general)
Number of subjects: 72
Study 17372318 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP composition (fat content)
Number of subjects: 72
Study 17372318 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP consumption frequency
Number of subjects: 72
Study 15080362 — intervention group
Group type: EXPERIMENTAL
Intervention: Packable composite resin (PCR) - Filtek P60 with Single Bond; mean bond strength 14.8 MPa ± 5.36
Number of subjects: 0
Study 15080362 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RMGIC) - Fuji II LC; mean bond strength 12.01 MPa ± 4.43
Number of subjects: 0
Study 15080362 — intervention group
Group type: COMPARATOR
Intervention: Cavity Conditioner applied to RMGIC; mean bond strength 11.94 MPa ± 4.60
Number of subjects: 0
Study 11695069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg twice daily
Number of subjects: 370
Study 11695069 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 250 mg morning, 500 mg evening
Number of subjects: 370
Study 11695069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 370
Study 11695069 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 370
Study 9137848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (200 mg/day, with slow dose-escalation starting at 25 mg/day for 2 weeks, then 50 mg/day for 2 weeks)
Number of subjects: 77
Study 9137848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 9137848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 77
Study 7899583 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 1‐alpha‐OHD3 plus 24,25(OH)2D3 (2 x 5 micrograms/day)
Number of subjects: 20
Study 7899583 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with 1‐alpha‐OHD3
Number of subjects: 20
Study 3035960 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of fenoterol (50 micrograms, 2 puffs, 4 times a day for 2.5 weeks)
Number of subjects: 33
Study 3035960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 2198436 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g of olestra twice a day
Number of subjects: 20
Study 2198436 — intervention group
Group type: COMPARATOR
Intervention: Butter
Number of subjects: 20
Study 30134777 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecoach-assisted exercise (TAE)
Number of subjects: 20
Study 30134777 — intervention group
Group type: COMPARATOR
Intervention: Self-regulated exercise (SRE)
Number of subjects: 20
Study 29641357 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE Plus
Number of subjects: 867
Study 29641357 — intervention group
Group type: COMPARATOR
Intervention: PACE
Number of subjects: 867
Study 29641357 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 867
Study 28017423 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality proficiency-based training on a virtual reality simulator (EyeSi) until a proficiency-based test was passed
Number of subjects: 18
Study 28017423 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 18
Study 26044291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Tenofovir Disoproxil Fumarate (TDF)
Number of subjects: 64
Study 26044291 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Tenofovir (TFV) gel
Number of subjects: 64
Study 26044291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral or vaginal)
Number of subjects: 64
Study 26044291 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 64
Study 23704191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (3 μg kg(‐1)) plus wound infiltration with 30 ml of 0.25% bupivacaine
Number of subjects: 60
Study 23704191 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with 3 μg kg(‐1) clonidine plus 30 ml of 0.25% bupivacaine
Number of subjects: 60
Study 23704191 — intervention group
Group type: COMPARATOR
Intervention: Control group (wound infiltration with 30 ml of 0.25% bupivacaine)
Number of subjects: 60
Study 23704191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (3 μg kg(‐1))
Number of subjects: 60
Study 23704191 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with 3 μg kg(‐1) clonidine
Number of subjects: 60
Study 21056535 — intervention group
Group type: EXPERIMENTAL
Intervention: Readaptation of the dorsolateral peritoneal layer (Group A, n=100)
Number of subjects: 200
Study 21056535 — intervention group
Group type: COMPARATOR
Intervention: No readaptation of the peritoneal layer (Group B, n=100)
Number of subjects: 200
Study 19670955 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated care management intervention
Number of subjects: 408
Study 19670955 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 408
Study 17200793 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Psychodynamic Psychotherapy
Number of subjects: 72
Study 17200793 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Therapy
Number of subjects: 72
Study 15161773 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5 mg/meal, maximum dose 4 mg/meal)
Number of subjects: 150
Study 15161773 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide (60 mg/meal, maximum dose 120 mg/meal)
Number of subjects: 150
Study 15161773 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 150
Study 15161773 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide
Number of subjects: 150
Study 11762413 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB389lL2 (Ontak) - a growth factor fusion toxin containing human interleukin-2 and diphtheria toxin
Number of subjects: 0
Study 11762413 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐Tac(Fv)‐PE38 (LMB‐2)
Number of subjects: 0
Study 11762413 — intervention group
Group type: EXPERIMENTAL
Intervention: RFB4(dsFv)‐PE38 (BL22)
Number of subjects: 0
Study 9628297 — intervention group
Group type: EXPERIMENTAL
Intervention: Curosurf (animal surfactant)
Number of subjects: 20
Study 9628297 — intervention group
Group type: COMPARATOR
Intervention: Exosurf (artificial surfactant)
Number of subjects: 20
Study 7892952 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tubal pyoinflammatory diseases
Number of subjects: 60
Study 7892952 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with persistent tubal inflammation
Number of subjects: 60
Study 7892952 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic suppurative process
Number of subjects: 60
Study 7892952 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 3364800 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline infusion (AI) after placebo (Pl) pretreatment
Number of subjects: 20
Study 3364800 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline infusion (AI) after diltiazem (D) pretreatment
Number of subjects: 20
Study 3364800 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline infusion (AI) after verapamil (V) pretreatment
Number of subjects: 20
Study 27046339 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CQ10)
Number of subjects: 124
Study 27046339 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 124
Study 27046339 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ10 + Trimetazidine
Number of subjects: 124
Study 24612148 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily for 12 weeks
Number of subjects: 511
Study 24612148 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily for 12 weeks
Number of subjects: 511
Study 24612148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study 23023841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-assisted intervention
Number of subjects: 164
Study 23023841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study 21177180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium infusion with continuous monitoring of T1, adjusted according to muscle relaxation monitoring.
Number of subjects: 60
Study 18484074 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 64
Study 18484074 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 64
Study 16141274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 16141274 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 15380170 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Information Leaflet (PIL)
Number of subjects: 995
Study 15380170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PIL)
Number of subjects: 995
Study 10360582 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression with prednisone (n=22)
Number of subjects: 45
Study 10360582 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppression without prednisone (n=23)
Number of subjects: 45
Study 8597678 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen 625 micrograms daily alone
Number of subjects: 321
Study 8597678 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine oestrogen 625 micrograms daily plus norgestrel 150 micrograms daily for the last 12 days of the 'cycle'
Number of subjects: 321
Study 1767903 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl combined with lignocaine 1.5% with adrenaline 1:200,000
Number of subjects: 200
Study 1767903 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine alone
Number of subjects: 200
Study 6760961 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly BCG and leukemia cell vaccine (group 1)
Number of subjects: 48
Study 6760961 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly BCG and leukemia cell vaccine (group 2)
Number of subjects: 48
Study 6760961 — intervention group
Group type: COMPARATOR
Intervention: Monthly BCG with no leukemia cell vaccine (group 3)
Number of subjects: 48
Study 31233281 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg monotherapy
Number of subjects: 423
Study 31233281 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib 4 mg plus MTX
Number of subjects: 423
Study 31233281 — intervention group
Group type: COMPARATOR
Intervention: MTX added to baricitinib
Number of subjects: 423
Study 29914954 — intervention group
Group type: EXPERIMENTAL
Intervention: LR-BAC (Low dose rabeprazole 10 mg b.i.d. + bismuth + amoxicillin + clarithromycin)
Number of subjects: 431
Study 29914954 — intervention group
Group type: EXPERIMENTAL
Intervention: LR-BAT (Low dose rabeprazole 10 mg b.i.d. + bismuth + amoxicillin + tetracycline)
Number of subjects: 431
Study 29914954 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-BAC (High dose rabeprazole 20 mg b.i.d. + bismuth + amoxicillin + clarithromycin)
Number of subjects: 431
Study 29914954 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-BAT (High dose rabeprazole 20 mg b.i.d. + bismuth + amoxicillin + tetracycline)
Number of subjects: 431
Study 26900776 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP
Number of subjects: 43
Study 26900776 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 43
Study 25396417 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS-MQ (mefloquine prophylaxis)
Number of subjects: 15
Study 25396417 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS-CQ (chloroquine prophylaxis)
Number of subjects: 15
Study 25396417 — intervention group
Group type: COMPARATOR
Intervention: Control (mefloquine prophylaxis with uninfected mosquitoes)
Number of subjects: 15
Study 23244208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocculine (homeopathic remedy)
Number of subjects: 431
Study 23244208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 21177506 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron/Folic Acid
Number of subjects: 676
Study 21177506 — intervention group
Group type: COMPARATOR
Intervention: Control (Vitamin A)
Number of subjects: 676
Study 17581267 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire cannulation technique (group II)
Number of subjects: 300
Study 17581267 — intervention group
Group type: COMPARATOR
Intervention: Conventional cannulation technique (group I)
Number of subjects: 300
Study 15803051 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus IVIG (Pentaglobin; 7 mL/kg/day for 5 days)
Number of subjects: 56
Study 15803051 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics plus 5% human albumin (control group)
Number of subjects: 56
Study 15803051 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG group
Number of subjects: 56
Study 15803051 — intervention group
Group type: COMPARATOR
Intervention: Control group (5% human albumin)
Number of subjects: 56
Study 12455736 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC[O2]
Number of subjects: 37
Study 12455736 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC[O2] during mechanical ventilation
Number of subjects: 37
Study 12455736 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated FRC[O2] measurements
Number of subjects: 37
Study 9594050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid
Number of subjects: 12
Study 9594050 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 7875477 — intervention group
Group type: EXPERIMENTAL
Intervention: Correctol (yellow phenolphthalein)
Number of subjects: 12
Study 7875477 — intervention group
Group type: EXPERIMENTAL
Intervention: Correctol (yellow phenolphthalein) with resin
Number of subjects: 12
Study 7875477 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 12
Study 7875477 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium sulfate
Number of subjects: 12
Study 2218657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE), 30 mg/kg/day
Number of subjects: 377
Study 2218657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (CEC), 40 mg/kg/day
Number of subjects: 377
Study 2218657 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate potassium (AMX-CL), 40 mg/kg/day
Number of subjects: 377
Study 2218657 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate potassium (AMX-CL)
Number of subjects: 377
Study 2218657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE)
Number of subjects: 377
Study 2218657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (CEC)
Number of subjects: 377
Study 348125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium glucose electrolyte solution (sodium concentration of 50 mmol/l)
Number of subjects: 39
Study 348125 — intervention group
Group type: COMPARATOR
Intervention: Standard oral solution (sodium concentration of 90 mmol/l)
Number of subjects: 39
Study 30651407 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible lumbar supports
Number of subjects: 28
Study 30651407 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (kinesiotape placed on the low back)
Number of subjects: 28
Study 28582812 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckwheat products
Number of subjects: 19
Study 28582812 — intervention group
Group type: COMPARATOR
Intervention: Normal gluten-free diet (Control)
Number of subjects: 19
Study 26124576 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser pulpotomy
Number of subjects: 30
Study 26124576 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery (ES)
Number of subjects: 30
Study 26124576 — intervention group
Group type: COMPARATOR
Intervention: Ferric sulfate (FS)
Number of subjects: 30
Study 23281658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 6 μg·kg(‐1)
Number of subjects: 218
Study 23281658 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 100 μg·kg(‐1)
Number of subjects: 218
Study 23281658 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received intravenous patient-controlled analgesia with fentanyl
Number of subjects: 218
Study 22106196 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcyn Rx alone
Number of subjects: 67
Study 22106196 — intervention group
Group type: COMPARATOR
Intervention: Oral levofloxacin plus normal saline wound irrigation
Number of subjects: 67
Study 22106196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin plus Microcyn Rx wound irrigation
Number of subjects: 67
Study 19491911 — intervention group
Group type: EXPERIMENTAL
Intervention: Riquent (abetimus sodium)
Number of subjects: 0
Study 17585038 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g/d of FS
Number of subjects: 44
Study 17585038 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g/d of FS
Number of subjects: 44
Study 17585038 — intervention group
Group type: COMPARATOR
Intervention: 72 g/d of CSB
Number of subjects: 44
Study 15482245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (1 MHz, 1.0 W/cm², pulse 1:4, 15 min/session)
Number of subjects: 50
Study 15482245 — intervention group
Group type: COMPARATOR
Intervention: Low level laser therapy (9 joules, 830 nm infrared laser at five points)
Number of subjects: 50
Study 11136956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapreotide (50-microg intravenous bolus followed by an infusion at a rate of 50 microg per hour for five days)
Number of subjects: 196
Study 11136956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapreotide
Number of subjects: 196
Study 11136956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 11136956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapreotide and endoscopic treatment
Number of subjects: 196
Study 11136956 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic treatment alone
Number of subjects: 196
Study 9489274 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR (n = 9)
Number of subjects: 26
Study 9489274 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo (n = 9)
Number of subjects: 26
Study 9489274 — intervention group
Group type: COMPARATOR
Intervention: Computerized exposure (control, n = 8)
Number of subjects: 26
Study 8852779 — intervention group
Group type: EXPERIMENTAL
Intervention: self-adhesive breast forms
Number of subjects: 67
Study 8852779 — intervention group
Group type: COMPARATOR
Intervention: customary breast forms
Number of subjects: 67
Study 2257060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR
Number of subjects: 35
Study 2257060 — intervention group
Group type: COMPARATOR
Intervention: Standard Sinemet (STD)
Number of subjects: 35
Study 7018328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (senior physician spent extra time discussing assessment and management, bypassed clerical procedures, promised continuity of care)
Number of subjects: 89
Study 7018328 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual treatment by emergency department nurses and residents)
Number of subjects: 89
Study 31530666 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Semaglutide 14 mg
Number of subjects: 822
Study 31530666 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin 25 mg
Number of subjects: 822
Study 28325630 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (patient reluctance mentioned)
Number of subjects: 236
Study 28325630 — intervention group
Group type: COMPARATOR
Intervention: Control group (patient reluctance not mentioned)
Number of subjects: 236
Study 28325630 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence Based Practice (EBP) attitudes
Number of subjects: 236
Study 25640827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality foster care
Number of subjects: 102
Study 25640827 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 102
Study 25640827 — intervention group
Group type: EXPERIMENTAL
Intervention: Long allele carriers (both groups)
Number of subjects: 102
Study 24823330 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine intestinal submucosa (SIS)
Number of subjects: 5
Study 24823330 — intervention group
Group type: COMPARATOR
Intervention: Silver-containing cellulose hydrofiber (AgH)
Number of subjects: 5
Study 21316157 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive normative feedback (Intervention Group)
Number of subjects: 158
Study 21316157 — intervention group
Group type: COMPARATOR
Intervention: Very brief feedback (Control Group)
Number of subjects: 158
Study 21316157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 158
Study 19618688 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA fortified wheat flour
Number of subjects: 400
Study 19618688 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4 fortified wheat flour
Number of subjects: 400